Clearance of the SARS-CoV-2 virus in an immunocompromised patient mediated by convalescent plasma without B-cell recovery

Maamoun Basheer, Elias Saad, Orly Laskar, Ofir Schuster, Hagai Rechnitzer, Simona Zisman-Rozen, David Azoulay, Nimer Assy

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Coronavirus disease (COVID-19) is a contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, which depletes B lymphocyte cells and therefore disables the production of neutralizing antibodies. The combined use of external anti-viral agents like convalescent plasma, IVIG and Remdesivir successfully helped the patient’s immune system to eradicate the virus without B-cell population recovery. In vitro studies showed that convalescent plasma is the main agent that helped in eradicating the virus.

Original languageEnglish
Article number8902
JournalInternational Journal of Molecular Sciences
Volume22
Issue number16
DOIs
StatePublished - 18 Aug 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

  • Immunocompromised
  • Pneumonia
  • SARS-COV-2
  • T lymphocytes

Fingerprint

Dive into the research topics of 'Clearance of the SARS-CoV-2 virus in an immunocompromised patient mediated by convalescent plasma without B-cell recovery'. Together they form a unique fingerprint.

Cite this